XYD224: A BRD9 Degrader Compound with In Vivo Antitumor Activity

Xin Tang published a dataset on figshare in May 2026 describing the compound XYD224 (compound 27), a potent BRD9 degrader. The data likely contains results from in vitro and in vivo experiments, including IC50 values and tumor growth inhibition rates. The dataset is 225.0 KB in size and includes PDB format files.

Use Cases

• Analyze structure-activity relationships for BRD9-targeting PROTACs based on the described compound series.
• Validate in vitro potency metrics like IC50 values against AML cell lines mentioned in the description.
• Assess in vivo efficacy using tumor growth inhibition rates from the MV4-11 xenograft model.
• Study degradation mechanisms based on described time-, dose-, CRBN-, and proteasome-dependent effects.

Strengths

• Includes specific quantitative results, such as an IC50 of 33 nM in MV4-11 cells.
• Reports in vivo efficacy with tumor growth inhibition rates of 70% and 79% at two dose levels.
• Data is associated with a specific, well-characterized compound (XYD224/compound 27).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (225.0 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental data from the design, synthesis, and evaluation of a series of BRD9 PROTACs.

Freshness

Last updated 2026-05-28 05:15:46; freshness should be verified.